Patent Profits Could Flow from $TPIV’s TAP
October 3rd, 2009 at 8:38 am Posted by
It’s the weekend students and The Dean’s got $TPIV on TAP!
$TPIV‘s vaccines are immunotherapies that allow cancer cells to become identifiable to a patient’s immune system, which will then attack and kill the cancerous cells.
The American Cancer Society reports that cancer accounts for 23% of all deaths in the United States and estimates that nearly 2 million will die from cancer in North America this year.
The Dean’s excited to bring the CollegeStock Community $TPIV because the company has more than one product and guess what else—more than one PATENT for their technologies.
US Patent No. 6,361,770 gives $TPIV protection for their TAP-1 product as a therapy to fight all types of cancers with different delivery mechanism in not just the United States but France, Germany, the United Kingdom, Switzerland and is pending in Japan.
$TPIV‘s second patent (US Patent No. 5,792,604) is valid in the United States, Canada, Japan and Europe and protects a screening process that identifies compounds that strengthen the immune system to fight cancer and infectious diseases.
And $TPIV has filed several applications for a number of novel aspects of their technologies. To make all of these things possible, $TPIV just brought in $450,000 in working capital for clinical development programs, acquisition of more technologies and expanding their patents globally.
$TPIV CEO Denis Corin suggests that their technologies have proven to improve the immune system’s ability to recognize and kill cancer. As The Dean has told the CollegeStock Community before, smart money invests in people and $TPIV just assigned Tracy A. Moore as their new CFO.
The Dean believes that $TPIV‘s restructuring in management and financing puts them in a position to further develop their therapies for cancer and infectious diseases. The Dean thinks the profit potential for $TPIV comes with their TAP technology capable of boosting the immune system to fight off cancer, HIV and Smallpox.
Especially with the scare of the H1N1 Swine Flu virus hanging overhead, The Dean believes more government funding will allow further combined research efforts. Just this past week, President Obama approved $5 billion for HIV/AIDS research.
Several world powers are pumping billions of dollars into the global economy and The Dean believes there’s plenty of money left to be pumped into cancer research.
The Dean has done his homework and knows that 25% to 30% of all cancer deaths could be prevented with earlier diagnosis and more effective treatments AND $TPIV‘s working to provide the world with both.
SIGN UP TODAY and get in at the start of The Dean’s first ever Scholarship Fund contest. To be eligible, you MUST be an Honors Student. With The Dean giving away $5,000 to one top-performing Honors Students every quarter, $9.87/month to register for Honors Class is the ONLY way to get to the head of the class.
